Discovery of Novel Thiophene-Based Baloxavir Derivatives as Potent Cap-Dependent Endonuclease Inhibitors for Influenza Treatment
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Yongzhi Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, Shenzhen Grubbs Institute and Medi-X Pingshan, South…. Hauptthemen laut MEDLINE: Antiviral Agents, Thiophenes, Mice, Inbred BALB C, Dibenzothiepins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Guangdong Provincial Department of Science and Technology, National Key Research and Development Program of China, China Academy of Chinese Medical Sciences.
Abstract (Originalsprache)
The genetic recombination and antigenic variation of influenza viruses may decrease the efficacy of antiviral vaccines, highlighting the imperativeness of developing novel anti-influenza agents. Herein, a series of thiophene-based compounds were designed and synthesized as potent anti-influenza agents. Among them, ATV2301 exhibited an excellent anti-influenza activity (EC50, H1N1 = 1.88 nM, H3N2 = 4.77 nM), a higher safety index (SI, H1N1 = 18218, H3N2 = 7180), and a remarkably improved oral bioavailability (F = 71.60%). The prodrug ATV2301A demonstrated strong therapeutic efficacy and protection in H1N1-infected BALB/c mice, with low toxicity and broad tissue distribution. ATV2301 also exhibited high stability in both human and mouse liver microsomes. Mechanistic studies indicated that ATV2301's anti-influenza activity was due to its effects on polymerase acid protein (PA), nuclear protein (NP), and RNA-dependent RNA polymerase (RdRp). Additionally, ATV2301 showed potent activities against clinical isolates of anti-influenza A virus (IAV) and anti-influenza B virus (IBV), positioning it as a promising cap-dependent endonuclease inhibitor for further clinical research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, Shenzhen Grubbs Institute and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen 518000, China.
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- Shenzhen AntiV Pharma Co., Ltd., Shenzhen, Guangdong 518081, China.
- Guangzhou National Laboratory, Guangzhou, Guangdong 510005, China.
- State Key Laboratory of Organ Failure Research, Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou 510515, China.
ORCID-Profile: Shuwen Liu, Xumu Zhang
Förderung
- Guangdong Provincial Department of Science and Technology
- National Key Research and Development Program of China
- China Academy of Chinese Medical Sciences
- High Level of Special Funds
- Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Southern University of Science and Technology
Zitieren
APA
Chen, Y., Lu, K., Rong, B., Wen, Y., Li, G., Li, S., Guo, D., Zhou, Q., Liu, S., & Zhang, X. (2024). Discovery of Novel Thiophene-Based Baloxavir Derivatives as Potent Cap-Dependent Endonuclease Inhibitors for Influenza Treatment. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01979
Vancouver
Chen Y, Lu K, Rong B, Wen Y, Li G, Li S, et al. Discovery of Novel Thiophene-Based Baloxavir Derivatives as Potent Cap-Dependent Endonuclease Inhibitors for Influenza Treatment. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01979
BibTeX
@article{Chen2024,
author = {Chen, Yongzhi and Lu, Kunyu and Rong, Binhao and Wen, Yuanmei and Li, Guanguan and Li, Shuo and Guo, Deyin and Zhou, Qifan and Liu, Shuwen and Zhang, Xumu},
title = {Discovery of Novel Thiophene-Based Baloxavir Derivatives as Potent Cap-Dependent Endonuclease Inhibitors for Influenza Treatment},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01979}
}
EUVIMED